Carbamazepin (Carbamazepine)

Generic Name

Carbamazepine

Brand Names

Carbamazepin, Carbatrol, Equetro, Tegretol

FDA approval date: March 11, 1968

Classification: Mood Stabilizer

Form: Tablet, Suspension, Capsule

What is Carbamazepin (Carbamazepine)?

Epilepsy Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology . Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures . Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures do not appear to be controlled by carbamazepine. Trigeminal Neuralgia Carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

A Prospective, Real-World Evidence, Multicenter Study to Evaluate the Efficacy and Safety of Eslicarbazepine in Managing Epilepsy

Enrollment Status: Recruiting

Publish Date: August 28, 2026

Intervention Type: Drug

Summary: This prospective multicenter observational study will evaluate the effectiveness, safety, tolerability, and impact on quality of life of eslicarbazepine in adults with focal-onset seizures in routine clinical practice. Participants will include newly diagnosed patients and patients previously treated with carbamazepine or oxcarbazepine who have inadequate seizure control or intolerable adverse eff...

A Phase 1, 4-arm, Open-label, Drug-drug Interaction Trial to Evaluate the Pharmacokinetics of Repinatrabit Oral Tablets When Co-administered With Ethinyl Estradiol/Norethindrone, Metformin, Carbamazepine, Rosuvastatin, and Methotrexate in Healthy Participants

Enrollment Status: Recruiting

Publish Date: August 12, 2026

Intervention Type: Drug

Study Phase: Phase 1

Summary: The purpose of this study is to assess the drug-drug interaction (DDI) of repinatrabit with ethinyl estradiol/norethindrone or norethisterone (EE/NE), metformin, rosuvastatin, carbamazepine, and methotrexate in healthy participants.

Physiological-based Pharmacokinetics Approach to Determine the Extent of Drug Exposure of Antiseizure Medications During Pregnancy and Breastfeeding

Enrollment Status: Recruiting

Publish Date: May 06, 2026

Intervention Type: Drug

Summary: This project focuses on anti-seizure medication (ASM) clearance and physiological factors determining blood concentrations in pregnant adult women with epilepsy and amounts of exposure to their unborn children and nursing infants.

View All Clinical Trials